Christine Sakdalan

⏩2024 Healthcare Change Maker: Madi Vanstone https://lnkd.in/gmhEHH5U For more than half of her young life, Madi, 22, has been fighting for access to life-changing treatments for #cystic #fibrosis. Diagnosed with the condition at 8 months old, Madi had the opportunity to enrol in a clinical trial for a novel CF treatment called Kalydeco a decade later. Just one problem: after the trial ended, Madi could no longer receive the costly drug without paying for it. She and her mother spent two years lobbying the Ontario government before they agreed to cover it. In the meantime, Madi’s family, supported by fundraising efforts in her community, had to cover a good portion of the drug’s $300,000 annual cost. [see the full article for more] #specialtypharmaceuticals #Canada #patients #patientsfirst #healthoutcomes #data #healthcare #pharmaceuticalindustry #outcomes #innovation #access #drug #drugaccess #realworldevidence CC: Beth Vanstone Cystic Fibrosis Canada / Fibrose kystique Canada CF Get Loud

23

Hahahaha - oh, this is rich. The mission statement from one of the priciest consulting groups around. And the audacity to open it up with, OUR MISSION IS CLEAR: Our mission is clear. We go deep to unlock insight and have the courage to act. We bring the right people together to challenge established thinking and drive transformation. We work with our clients to build the capabilities that enable organizations to achieve sustainable advantage. We are shaping the future. Together. (translation: we trade lotsa jargon for lotsa dollars)

2

2 Comments

"IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion." #Biosimilars #Adalimumab like #Hulio from #BioconBiologics can provide #affordable #access to #patients and save billions for the Government. #Biosimilars are the way forward for affordable biologics therapy. Read the article: US Specific "The biosimilar Hulio was offered last year at a WAC of $498 for a month's supply, versus $3,461 for Humira, according to a Samsung Bioepis biosimilar report. Still, the vast majority of prescriptions filled in 2023 were for the Humira originator product, prompting market research group IQVIA to conclude that “maintaining patients on Humira comes at a cost of up to about $6 billion per year for patients and employers, compared to a full transition to adalimumab biosimilars.” Biocon Biologics Matt Erick Joshua Salsi https://lnkd.in/gN74FShF

33

The right connection can be life-changing. I've signed-up to Ziff Davis Mentorship Program, and I look forward to making meaningful connections, sharing, and learning. #mentoring #Mentorloop Mentorloop

1

“Voice in the wilderness” is an idiom for when someone expresses an idea or opinion, which is then ignored // More than ever, healthcare organizations are asking patients about their lived experience. But how does that information get used? Read on to learn more: https://lnkd.in/gV5pfwiE #patients #patientvoice #patientsfirst #drugs #pharmaceuticals #specialtypharmaceuticals #Canada #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #pharmaceuticalindustry #outcomes #innovation #access #drug #drugaccess #healthcare CC: Arif Mitha 20Sense | Consulting

8

2 Comments

Election Time: A Marketer’s Perspective on Surveys and Insights   Election seasons offer fascinating insights—not just into politics but also into marketing. As marketers, we often rely on surveys and qualitative interviews to understand the minds of our customers. These insights guide the strategies we develop to shape our brand and business direction. Surveys and Market Research are A Cornerstone for Business Growth   They add significant value to any business. They offer unbiased insights into customer behavior and preferences, helping validate the hypotheses we develop as marketers. These insights act as lead indicators of emerging trends that we might otherwise overlook. They also guide in product development, marketing strategies, and positioning efforts to align better with market expectations. Market research also serves as a safety net—minimizing the risks associated with decision-making. However there are a few pitfalls we should be careful about. I recently read an insightful article by T.C.A. Anant, former Chief Statistician of India, where he highlighted some common errors in surveys. His perspective, coming from such a well-respected figure in the field, is worth reflecting upon. He explains that every survey is shaped by two participants—the interviewer and the respondent—each bringing unique perspectives to the conversation. Here are three critical points he raises: Language Barriers Beyond Words: Communication goes beyond just linguistic translation; it includes the nuances of how both parties interpret and respond to questions. Social Settings Shape Conversations: Interviews don’t occur in isolation. The environment influences the responses and the overall outcome. Interviewer Training Affects Accuracy: The quality of results hinges heavily on how well the interviewers are trained and prepared for the task. Anant shares an interesting anecdote. In a village in Palampur, where many socioeconomic studies are conducted, the residents had become so accustomed to surveys that they would ask scholars, "Aap questions MPhil ke liye pooch rahe ho ya PhD ke liye?" (Are you asking these questions for an MPhil or a PhD?). Their responses would then be tailored accordingly—demonstrating how savvy respondents can affect survey outcomes. The Power of Balanced Market Understanding   In my experience with both quantitative and qualitative research, I’ve encountered similar challenges. While selecting the right agency is crucial, building your own insights remains even more critical. WhiteSpace Consulting & Capability Building we always advise : market research and real-world customer interactions complement each other. It is never either OR, it is always AND What’s your take? How do you balance formal research with building your own insights?   https://lnkd.in/d6iUB5q3

9

1 Comment

Great actionable ideas from Tim Mitchell and Mike Melnick on how to apply omnichannel principles and experience design to take Medical Affairs to the next step in its evolution. Check out their MedXD framework!

3

Curious about what we’re working on at Cheemia ReSET, industry insights, and my personal musings?😎 Sign up for the Cheemia ReSET monthly e-newsletter to stay in the loop! 📧 You’ll get the latest updates, details about our upcoming Digital Transformation Series LinkedIn Live, and all things HCP engagement that matter to you. Subscribe here: www.cheemiareset.com (scroll to the bottom of the page) #CheemiaReSET #DigitalTransformation #Pharma #Pharmaceuticals

19

Actualizing Better Health and Health Care for Older Adults As the U.S. population ages, with those over sixty-five projected to outnumber those under five by 2030, our healthcare system faces critical challenges. The COVID-19 pandemic has further highlighted the need for a robust response to the complexities of aging. In response, the National Academy of Medicine's Vital Directions for Health and Health Care: Priorities for 2021 initiative has outlined six key directions to enhance care and quality of life for older Americans: Develop a Prepared Workforce: Create a healthcare workforce equipped to meet the needs of a diverse and growing older population. Strengthen Public Health: Improve public health strategies to address the specific needs of older adults. Address Disparities and Inequities: Focus on reducing health disparities and ensuring equitable access to care. Innovate Care Delivery: Implement and evaluate new approaches to delivering care that are tailored to older adults. Allocate Resources Effectively: Ensure resources are directed toward patient-centered care, including palliative and end-of-life care. Redesign Long-Term Services and Supports: Reform the structure and financing of long-term care to better support older adults. By addressing these priorities, we can build a healthcare system that promotes better health outcomes and respects the preferences and needs of older adults. Visit www.tibpharmacy.com or call (510)-573-0064 to learn more about how we can support your well-being. Let's journey towards better health together! #TIBPharmacy #HealthAsWeAge #Multivitamins #NutritionForSeniors #LongTermCare #MedicationManagement #BetterHealth #Teamwork #TIBPharmacy #NewarkPharmacy #pharmacyservices #longtermcare #LTCPharmacyEndOfLifeCare #ltcathome #hospicespecialized #LTCPharmacy #HospicePharmacy #ltcspecialized #MedicationManagement #PackagingPower #SimplifyYourHealth #health #wellness

8

3 Comments

2023 was a banner year for digital health, especially in terms of technological innovations. At the same time we also witnessed the largest ever number of FDA approvals on novel medical devices in a single year. This list included a number of AI-enabled digital health products, among others. Read the article below for a full summary of how R&D and healthcare can change in the future.

2

‘If it’s like this, I don’t do it anymore’ (angry stomping) Practicing energy tools for ourselves can sometimes feel that it is failing us. Whether these are for protection, healing, balance, intention setting, realizing our goals etc. it applies to all A/ it is normal, we all go through it, ans some of us are more patient than others. It happened to me many times and that’s then the frustrated and angry Emilie reaction 👆😂 B/ it may not be true that it is failing us, we just don’t see the bigger picture yet. Jeffrey Allen is explaining this very nicely in the below 👇 and giving very helpful tips for when you are in such a situation. Worth watching for those of you that are practicing. Enjoy and keep going! 🌞 #energyhealing #energymanagement #energycoaching

6

As we move past the 4th of July holiday, it's crucial to pause for a mid-year review of trends shaping our biopharma industry: Growth of Advanced Modalities: Biopharma companies are heavily investing in cutting-edge treatments like gene therapies and RNA-based therapeutics, paving the way for addressing previously untreatable diseases. Global Pricing Pressure: Pricing negotiations remain complex as governments, payers, and patients demand transparency and affordability, challenging companies to balance innovation and access to life-saving therapies. Evolving Commercialization Models: The shift towards direct-to-consumer approaches, digital marketing, and patient-centric strategies is transforming traditional commercialization models, accelerated by telemedicine and virtual engagement trends from the recent pandemic. Focus on Patient Diagnosis and Biomarkers: Biomarker-driven endpoints in clinical trials are on the rise, optimizing patient outcomes through tailored treatments and minimizing adverse effects. Evolving Financing Landscape: Biopharma firms are diversifying financing sources through partnerships, licensing deals, and public offerings, with special purpose acquisition companies (SPACs) influencing funding strategies. The biopharma industry's dynamic nature requires adaptable partners. Discover how WEP Clinical can support your success amidst these industry shifts at wepclinical.com. Let's connect and discuss how we can excel together in these changing times.

12

Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst

28

With the amount of data collected daily in healthcare provision, and the complex decision making throughout the system, AI holds great promise in this industry. And yet, disruption has been slow and steady, rather than transformational, over the last decade. A great interview well worth the full watch examines some of the challenges, and paths forward to AI in the US healthcare ecosystem. Gaining he “trust” of practitioners is particularly salient, with the recommendation to build models with engagement and endorsement of physicians, makes a ton of practical sense.

54

3 Comments

Not an uncommon experience with #insurance and #priorauthorization. Think about the steps to a #specialty mail order medication: Day 1: 1. Doctor writes prescription and sends to patient's preferred pharmacy. 2. The insurance rejects the claim and directs the patient to a "specialty" pharmacy. Day 2-3: 3. Patient tries to get prescription transferred (if electronic or verbal) to specialty pharmacy or mails hardcopy. 3b. Patient chooses instead to call doctor and ask for a new prescription to be sent to the specialty pharmacy. Day 3-5: 4. Doctor sends prescription #2 to the specialty pharmacy. 5. Prescription rejects for prior authorization. (It's now at the "right" pharmacy, but the formulary requires a review by the insurance). 6. The pharmacy contacts doctor and informs patient. Day 5-8: 7. After much back and forth, PA forms, missing information, clarifications, follow up calls by the patient to the doctor and insurance, by the doctor to the insurance, and by the patient to the pharmacy, an approval is granted. 8. Because the member has a plan with a deductible that is not met, their cost-share for the approved medication is $1000+. Day 9-10: 9. Patient receives medication in the mail. 10 days is being generous. Many patients get lost in the shuffle, may wait until their next doctor appt, or never get the prescription at all. Little did the patient know they could have just paid $80 cash at their original pharmacy without a prior authorization. The patient would have received the medication on Day 1 at their preferred pharmacy at a fraction of the cost. The numbers used are for representative purposes only and may sound like an egregious variance, but it exists. Seeing many examples throughout my career serve as motivation to do something about it. #getgreenback #greenbackhealth #pricemymeds

9

3 Comments

#PrimaryCare must thrive, but the question is how? A panel of executives convened at #HLTH recently to answer this question. It’s encouraging to see key factors like meeting patients where they are and developing creative partnerships among the influences that can help primary care evolve to meet consumer preferences. https://lnkd.in/ekuJiu7k

5

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit. ....from the Citeline archives, via Sarah Karlin-Smith ********** In a court filing reported yesterday by Bloomberg Law reporter Celine Castronuovo, Amgen argues it will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for Enbrel. Like nearly all content in healthcare today, Amgen's storyline starts and sticks with the Standard Model, the cut-and-paste messaging that now sits at the extreme end of monotonous repetition. To wit: "Innovative medicines have enhanced and extended the lives of countless Coloradans. Recognizing the enormous investment of time and money needed to discover and develop these novel treatments, Congress rewarded those who bring new medicines to market with a period of patent exclusivity and pricing discretion. As numerous scholars have observed, the economic incentives provided by the federal patent system are crucial to Congress’s objective of promoting pharmaceutical research and development. One such medicine, Amgen’s pioneering drug ENBREL® provides life-changing relief to thousands of Coloradans who suffer from arthritis and other autoimmune diseases. Enbrel redefined the clinical course of moderate to severe rheumatoid arthritis...." etc., etc., etc., etc. All of which may be technically true, as "the scholars have observed", but if the objective for Amgen is an argument that persuades, the #StandardModel stopped working long ago. It also doesn't help when the 20 members of the Colorado drug pricing board and its advisory council come home from work and watch the local news, where the commercial breaks will be flooded with drug promotion, part of the media buy that comes from the industry spending $30 billion/year on DTC advertising. These things are connected. In a conversation with Bill Boulding, Dean of Duke University - The Fuqua School of Business around the same time as his interview with STAT, Frazier said one of the role's of business was in collaborating with government to reinvent the country. “The role of the private sector in the United States in helping to reinvent this country, over, and over, and over again, is important,” he said. “I think business has the talent, it has the resources, it has the capabilities of helping to change our country.” It's time to sweep the old concepts out of the saddle. The faster the drug market learns how to connect things differently, to 'see, say, sell and sustain' strategy at a system level, the faster it can start creating a different future for itself. #QuentinTarantino

10

1 Comment